NCT03235973RecruitingPhase 1
CLADRIBINE DOSE ESCALATION IN CONDITIONING REGIMEN PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (Allo-HSCT) FOR REFRACTORY ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROMES
Source: EU CTIS (euclinicaltrials.eu) · Last updated 21 May 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 29 (estimated)
- First submitted
- 23 Aug 2024
- Start date
- 7 Oct 2024
- Lead sponsor
- Institut Paoli Calmettes
- Diseases
- Myelodysplastic syndromes
- NCT number
- NCT03235973
- EU CT number
- 2024-515737-14-00
- EudraCT number
- 2016-004127-23
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 29
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Paoli-Calmettes Coordinator of this site? Confirm its status | Marseille | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.